N2770
p-Nitrophenyl phosphate
SIGMAFAST™, chromogenic, tablet
Synonym(s):
pNPP tablets
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
product name
SIGMAFAST™ p-Nitrophenyl phosphate Tablets, tablet, To prepare 20 mL
Quality Level
form
tablet
solubility
water: 0.25 tablet/mL, clear, colorless
storage temp.
−20°C
Looking for similar products? Visit Product Comparison Guide
Application
Developed for use as a soluble substrate for the detection of alkaline phosphatase activity in Enzyme Immunoassays (EIA). pNPP is the substrate of choice in high sensitivity alkaline phosphatase-based EIA assays.One pNPP tablet and one Tris buffer tablet are dissolved in deionized water and provide a ready-to-use substrate. Each Sigma FAST pNPP tablet set yields a solution containing 1.0 mg/ml pNPP, 0.2 M Tris buffer. EIA applications using pNPP may be read in timed assays or stopped with 3N NaOH for delayed readings. SIGMAFAST™ require only the addition of distilled or deionized water to prepare an active substrate solution. Tablets are individually packaged in foil packets.
Reconstitution
Each tablet set dissolved in 20 mL deionized water yields a ready-to-use buffered solution containing pNPP.
Legal Information
SIGMAFAST is a trademark of Sigma-Aldrich Co. LLC
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
G Gasperini et al.
Infection and immunity, 89(4) (2020-12-16)
Typhoid and paratyphoid fevers have a high incidence worldwide and coexist in many geographical areas, especially in low-middle-income countries (LMIC) in South and Southeast Asia. There is extensive consensus on the urgent need for better and affordable vaccines against systemic
Fredman González et al.
medRxiv : the preprint server for health sciences (2021-05-06)
New information is emerging about SARS-CoV-2 epidemiology and immunity, but little of this information comes from low- and middle-income countries or from patients receiving care in the outpatient setting. The current study investigated the SARS-CoV-2 infection status and antibody responses
Phillipp Hartmann et al.
Frontiers in physiology, 12, 699253-699253 (2021-08-06)
Alcohol-associated liver disease (ALD) is an important cause of morbidity and mortality worldwide. The intestinal microbiota is involved in the development and progression of ALD; however, little is known about commensal fungi therein. We studied the dynamic changes of the
Fernando Diaz et al.
Virology, 513, 129-135 (2017-10-27)
Herpes simplex virus 2 (HSV-2) is the leading cause of genital herpes and increases the risk of HIV infection, but there is no effective vaccine. A replication-defective HSV-2 mutant virus, dl5-29, is effective in animal models and has been in
Roberta Di Benedetto et al.
International journal of molecular sciences, 22(19) (2021-10-14)
Outer Membrane Vesicles (OMV) constitute a promising platform for the development of efficient vaccines. OMV can be decorated with heterologous antigens (proteins or polysaccharides), becoming attractive novel carriers for the development of multicomponent vaccines. Chemical conjugation represents a tool for
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service